Please login to the form below

Not currently logged in
Email:
Password:

tau

This page shows the latest tau news and features for those working in and with pharma, biotech and healthcare.

AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies

AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies

An initial deal was forged in 2018 for the research and development of vectorised antibodies for Alzheimer’s focused on reducing tau, a protein which is slowly emerging as a new ... Through the tau and alpha-synuclein collaborations, we believe we have

Latest news

More from news
Approximately 3 fully matching, plus 41 partially matching documents found.

Latest Intelligence

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    gene-editing specialist Sangamo for rights to tau-targeting drug ST-501 as part of a broader R&D alliance. ... Tau is emerging as a target for drug development in Alzheimer’s, as well as other disorders like frontotemporal dementia.

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimer’s ahead of a cure

    Forward thinking. Researchers are now looking to other causes of Alzheimer’s outside Abeta proteins, with more focus on other possible links, including a protein called tau, which is now thought

  • A roadmap to the successful treatment of Alzheimer’s disease A roadmap to the successful treatment of Alzheimer’s disease

    This is being addressed through multiple Tau research programmes in early and late stage disease, including small molecules intervening at the first step of Tau pathology inside the cell. ... It has long been known that brain immune cells called

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    disease. Targeting tau. Tau is among the beneficiaries of the broader focus and emerging interest in combination therapies. ... Abeta plaques and neurofibrillary tangles of tau proteins are the two main pathological features.

  • Deal Watch January 2018

    Under this transaction Takeda gains options to three Denali programmes for neurodegenerative disorders: the ATV: BACE1/Tau and ATV: TREM2 programmes, which are both at preclinical stage for Alzheimer's disease, ... Acquisition company. 4, 800. Denali

More from intelligence
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest appointments

  • Pharma industry appointments Pharma industry appointments

    Lemus was also chief executive officer of Sigma Tau Pharmaceuticals and chief financial officer and executive vice president of MorphoSys, where he took the company public in 1999.

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    Ryan brings over 15 years of central nervous system clinical research experience to the role, and takes on responsibility for Asceneuron's pipeline of innovative small molecules and progressing tau modifiers ... His outstanding track record and expertise

  • Nanobiotix strengthens US leadership team Nanobiotix strengthens US leadership team

    He has also served as vice president and head of clinical development oncology at MannKind, and held clinical leadership positions at MedImmune and Sigma-Tau Research.

  • Sigma-Tau Pharmaceuticals appoints CEO Sigma-Tau Pharmaceuticals appoints CEO

    Rare disease specialist Sigma-Tau Pharmaceuticals has appointed Michael Minarich as chief executive officer. ... Prior to joining Sigma-Tau, Micharich was the Pharmacia Corporation's market company president in the Czech Republic and oversaw the merger

  • EMA names new head of legal service EMA names new head of legal service

    An Italian national, Marino has extensive legal experience in the pahrma industry, having served as director of corporate legal and intellectual property at pharma firm Sigma-Tau since 1997.

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

OPEN Health delivers over 250 virtual activities during COVID-19 – A clear path forward
...
Can eLearning improve patient recruitment and retention?
Some patients will still want to read pages of informed consent forms before joining a clinical trial, or want timely updates on paper rather than a notification on their phone....
How Far Do You Want To Go?
Join OPEN Health's virtual careers event on Tuesday 10th November, 15:00–17:00 GMT and discover where a career in medical communications could take you…...

Infographics